Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
ID05773001

Macrophage Regulation of Ozone-Induced Lung Inflammation

Led by Robert Tighe, MD · Updated on 2026-05-15

100

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

R

Robert Tighe, MD

Lead Sponsor

N

National Institutes of Health (NIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research investigates how past respiratory infections influence the risk of lung inflammation after exposure to environmental agents like ozone. The study focuses on adults aged 18 to 55 and aims to understand changes in lung immune cells, specifically macrophages, following these exposures. Participants are grouped based on their history of respiratory viral infections, including no infection, mild infection, or viral pneumonia recovery. Participants undergo an initial 1-day screening involving blood tests and breathing assessments. They then return for two separate 2-day testing series spaced 18 to 20 days apart. During these visits, participants experience inhaled challenges with either filtered air or ozone while performing alternating rest and treadmill walking for 135 minutes. After each challenge, lung evaluation includes blood draws, breathing tests, and bronchoscopy. Follow-up phone calls occur 24 hours after each test series. The study measures changes in specific lung macrophage populations at baseline and after the exposures. Participants are monitored for lung function and immune responses over about one to one-and-a-half months. The study includes safety monitoring and excludes individuals with ongoing lung issues or recent infections. The goal is to better understand lung inflammation related to environmental exposures and prior infections.

CONDITIONS

Brief Title

Macrophage Regulation of Ozone-Induced Lung Inflammation

Who Can Participate

Age: 18Years - 55Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Individuals between 18-55 years of age
  • Individuals with known prior respiratory viral infection history allowing classification into one of three groups:
    • No history of respiratory viral infection
    • Documented mild respiratory viral infection with mild or no symptoms and no lower respiratory tract infection
    • History of respiratory viral pneumonia with recovery, at least 6 months post-infection, and normal lung function
Not Eligible

You will not qualify if you...

  • Individuals with ongoing respiratory symptoms, supplemental oxygen use, or abnormal lung function after respiratory viral pneumonia
  • Current smokers or those who smoked tobacco or e-cigarettes within the past 5 years
  • Pregnant or lactating women
  • Recent antibiotic use or upper respiratory infection within 4 weeks
  • College or graduate students/employees under direct supervision of study investigators
  • History of alcohol or illicit substance abuse
  • Chronic cardiopulmonary or other medical conditions as determined by investigators
  • Increased airway hyperresponsiveness at baseline (positive methacholine challenge with PC20 FEV1 < 4 mg/ml)
  • Use of antihistamines, NSAIDs, antioxidants, or supplemental vitamins within 1 week prior to and during testing period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 1 day

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Approximately 1 to 1.5 months total with two 2-day test series separated by 18 to 20 days

Participants undergo two series of testing involving blood draws, breathing tests, and exposure challenges with filtered air or ozone, including a bronchoscopy procedure to evaluate the lung after exposure.

Two 2-day series of testing visits, each visit lasting about 3 to 3.5 hours, plus follow-up phone calls 24 hours after each series

Trial Site Locations

Total: 1 location

1

Duke University Medical Center

Durham, North Carolina, United States, 27710

Actively Recruiting

Loading map...

Research Team

C

Claudia Salazar

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

NON_RANDOMIZED

Model

CROSSOVER

Primary Purpose

OTHER

Number of Arms

3

Similar Trials

Randomized, Double-blind, Placebo-controlled Trial Evaluatin...

Respiratory Viral Infection

Actively Recruiting

11 locations

Assessment of the Type I IFN Response in the Nasal Cavity Du...

Respiratory Viral Infection

Actively Recruiting

1 location

Dime La VerDAD: Verify, Debunk, and Disseminate

Influenza

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here